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Mouse Skin Tumor Initiation-Promotion
and Complete Carcinogenesis Bioassays:
Mechanisms and Biological Activities of
Emission Samples
by S. Nesnow,* L. L. Triplettt and T. J. Slagat
Extracts ofsoots obtained from various sources were applied to the skin ofmice in an effort to
identify carcinogens in these mixtures and to link these materials to the etiology of human
cancer. Samples of coal chimney soot, coke oven materials, industrial carbon black, oil shale
soot, and gasoline vehicle exhaust materials have been examined by this method.
The studies reported here have been constructed to compare the carcinogenic and tumorigenic
potency of extracts from various particulate emissions: coke ovens, diesel and gasoline vehicles
and a roofing tar pot. Automobile emission samples were obtained by collecting the diluted and
cooled exhaust on Teflon-coated glass fiber filters. Coke oven and roofing tar samples were
particulate emission samples collected by impaction and filtration. The organic components
associated with each ofthe particles were extracted with dichloromethane and dermally applied
to SENCAR mice. All agents were applied as tumor initiators by using a five-dose protocol.
Selected extracts were also applied as complete carcinogens and as tumor promotors. Statistical
analyses of the resulting tumor data were performed by using nonlinear Poisson and probit
models. The results from these experiments provide a suitable data base for comparative potency
estimation of complex mixtures.
Introduction
Experimental animal studies and epidemiological
studies provide evidence that certain chemicals
present in the environment either as pure chemi-
cals or in complex mixtures are a major contribut-
ing factor in the etiology of some human cancers.
For example, polycyclic aromatic hydrocarbons
(PAHs) are widespread contaminants in our envi-
ronment, occurring primarily as the result of com-
bustion and pyrolysis oforganic materials (e.g., the
burning of cigarettes, operation of coke ovens,
operation of automobiles, industrial combustion
processes, etc.). Concern over the prevalence of
PAHs has increased as evidence establishing the
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carcinogenicity of a significant number of these
compounds has accumulated. BesidesPAHs, awide
variety ofother structurally diverse environmental
chemicals (aromatic amines, nitrosamines, nitro-
samides, metals, aflatoxins, and many others) are
known to be carcinogenic (1).
Current information suggests that chemical car-
cinogenesis is a multistage process; in this regard,
one of the best studied models is the two-stage
carcinogenesis system in mouse skin. Skin tumors
can be induced by the sequential application of a
subthreshold dose ofa carcinogen (initiation phase)
followed by repetitive treatment with a noncar-
cinogenic tumor promoter (promotion phase). The
initiation phase requires only a single application of
either a direct or indirect carcinogen at a sub-
threshold dose and is essentially irreversible. The
promotion phase is brought about by repetitive
treatments afterinitiation and is initially reversible
but later irreversible. If an agent is given repeat-NESNOW, TRIPLETT AND SLAGA
edly by itself, the mouse skin system can also be
used to determine if the agent is a complete
carcinogen (i.e., if it has both tumor initiating and
promoting activities). In addition, if an agent is
given concurrently with a known complete carcino-
gen or tumor initiator, one can determine if the
agent as cocarcinogenic or cotumor-initiating activ-
ity or possibly even anticarcinogenic activity. Simi-
larly, if an agent is given concurrently with a
known tumor promoter, one can determine if the
agent has copromoting or antipromoting activity.
Furthermore, as in most carcinogenesis systems,
skin carcinogens may display additive or synergis-
tic effects. The skin system is an important model
not only for studying carcinogenesis and for the
bioassay of carcinogenic agents but also for study-
ing modifiers of carcinogenesis. The major disad-
vantage of the skin system (as of many other
carcinogenesis systems) is that some carcinogens
are tissue specific.
Recentlythegenerality oftwo-stage tumorinduc-
tion has been demonstrated in a number of experi-
mental carcinogenesis systems (e.g., liver, bladder,
lung, colon, esophagus, stomach, mammary gland,
pancreas, lung cells in culture) (2). A wide variety
of agents (e.g., diet, bile acids, hormones, saccha-
rin, L-tryptophan, phenobarbital, polychlorinated
biphenyls, polybrominated biphenyls, butylated
hydroxytoluene) have been used successfully as
promoters (2).
Among rodent species, mice are generally more
sensitive than rats and hamsters to skin carcino-
genesis by either the complete carcinogenesis pro-
tocol or the initiation-promotion protocol (Table 1)
(3,4). In mice, the complete carcinogenesis protocol
gives rise to alownumber ofpapillomas followed by
a high incidence of squamous cell carcinomas,
whereas the initiation-promotion protocol gives rise
to a large number of papillomas followed by a
moderate incidence of squamous cell carcinomas. In
rats, both the complete carcinogenesis and initi-
ation-promotion protocols give rise to basal cell
carcinomas and very few papillomas and squamous
cell carcinomas. In hamsters, the complete carcino-
genesis protocol produces mainly squamous cell
carcinomas and some melanomas, whereas the in-
itiation-promotion protocol produces mainly mel-
anomas.
PAHs are one of the major classes of chemical
carcinogens that have skin tumor initiating and/or
complete carcinogenic activity on mouse skin and
have been studied extensively in this system. Over
100 PAHs, PAH derivatives, and PAH metabolites
are known to be mouse skin tumor initiators and/or
complete carcinogens (5,6). Among these, moder-
ate to strong initiators and/or complete carcinogens
include 7,12-dimethyl benz(a)anthracene, DMBA,
3-methylcholanthrene, benzo(a)pyrene [B(a)P], 7-
methylbenz(a)anthracene, 5-methylchrysene, dibenz
(a,h)anthracene, dibenzo(a,h)pyrene, dibenzo(a,i)
pyrene, dibenzo(a,e)pyrene, benzo(a)phenanthrene,
dibenzo(a,j)anthracene, benzo(c)chrysene, benzo(g,h,
i)perylene, dibenzo(a,c)naphthacene, and 11-methyl-
cyclopenta(a)phenanthren-17-one (5, 6). Besides
PAHs, many other chemicals and chemical classes
are known to be tumor initiators and/or complete
carcinogens on mouse skin (Table 2) (5,6).
Tumor Initiation
When appropriately tested, known complete car-
cinogens in skin show skin tumor-initiating activity
(7). In the two-stage mouse skin system, initiation
is the only stage that requires the presence of the
complete carcinogen, and the measured complete
carcinogenic potency ofachemicalreflectsits capac-
ity for tumor initiation. There is both a good quali-
tative and quantitative correlation betweenthe com-
plete carcinogenic and tumor initiating activities of
several chemical carcinogens in mouse skin (7). This
relationship holds when one considers the number
of papillomas per mouse at early times (10 to 20
weeks) or the final incidence of carcinomas after
tumor initiation (7).
It is possible that a carcinogen lacking promoting
ability would not be detected when tested as a
complete carcinogen. It has been reported that a
numberofchemicalcompounds, e.g., benz(a)anthra-
Table 1. Comparison of complete carcinogenesis and initiation-promotion in the skin of various species.
Tumor histology
Species Treatment Basal cell carcinomas Carcinomas Papillomas Melanomas
Mouse Complete + + *+
Two-stage + + + + +
Rat Complete +
Two-stage +
Hamster Complete + +
Two-stage +
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Table 2. Chemicals other than polycyclic aromatic hydrocar-
bons that are positive as skin tumor initiators and/or com-
plete carcinogens.a
Class Chemical(s)
Aldehyde Malonaldehyde
Aziridine 3-Hydroxy-l-ethylaziridine
Carbamate Urethane
Vinyl carbamate
N-Butyl-N-nitrosourethane
Epoxide, diepoxide Glycidaldehyde
1,2,3,4-Diepoxybutane
1,2,4,5-Diepoxypentane
1,2,6,7-Diepoxyhexane
Chloroethylene oxide
1,2-Epoxybutyronitrile
Haloalkyl ether Bis(chloromethyl) ether
a,a-Dichloromethyl methyl ether
Chloromethyl methyl ether
Haloaromatic 2,3,4,5-Tetrachloronitrobenzene
2,3,4,6-Tetrachloronitrobenzene
2,3,5,6-Tetrachloronitrobenzene
Pentachloronitrobenzene
Haloalkyl ketone, acid Chloroacetone
3-Bromopropionic acid
Hydroxylamine N-Acetoxy-4-acetamidobiphenyl
N-Acetoxy-2-acetamidofluorene
N-Hydroxy-2-aminonaphthalene
N-Acetoxy-2-acetamidophenanthrene
N-(4-Methoxy)benzoyloxypiperadine
N-(4-Nitro)benzoyloxypiperadine
N-Acetoxy-2-acetamidostilbene
Lactone Propiolactone
Multifunctional Triethylenemelamine
4-Nitroquinoline-N-oxide
Natural product Aflatoxin Bi
Sterigmatocystin
Nitrosamide N-Methyl-N'-nitro-N-nitrosoguanidine
Sulfonate Allyl methylsulfonate
Sultone 1,3-Propanesultone
Urea N-Nitrosomethylurea
N-Nitrosoethylurea
aData of Pereira (5) and Nesnow (6).
cene, dibenz(a,c)anthracene, chrysene, triethylene-
melamine, urethane, B(a)P-7,8-dihydrodiol-9,10-
epoxide,benz(a)anthracene-3,4-dihydrodiol-1,2-epo-
xide, have mouse skin tumor-initiating activity but
either lack or have very weak complete carcino-
genic activity (6,7).
Many carcinogens produce good dose-response
relationships when bioassayed as tumor initiators
using SENCAR mice. For example, results for
DMBA and B(a)P (Table 3) (7) show good correla-
tions between the number ofpapillomas per mouse
at 15 weeks and the final carcinoma incidence at 50
weeks. For each agent the percentage ofmice wth
papillomas also shows a reasonable correlation, but
the dose response is very narrow. The SENCAR
mouse was derived by crossing Charles River CD-1
mice with skin tumor sensitive mice (originally
derived from Rockland mice) and selecting for sen-
sitivitytoDMBA-12-0-tetradecanoylphorbol-13-ac-
etate (TPA) two-stage carcinogenesis for 8 gener-
ations starting with the F1 cross as described by
Boutwell (7,8). Themicedevelopingthemostpapillo-
maswiththe shortestlatencyperiodafterinitiation-
promotion treatment were selected for each breed-
ing.
Experiments with B(a)P and DMBA using dif-
ferent stocks and strains of mice (9) suggest the
following ranking for sensitivity to two-stage (initi-
ation-promotion)carcinogenesis: SENCAR >> CD-1
> ICR/Ha Swiss > BALB/c
- C57BL/6
- C3H
-
DBA/2. It is important to emphasize the limitations
of this subjective ranking. Firstly, only responses
to B(a)P and DMBA were considered. Secondly,
dose-response data for both the carcinogen and/or
promoter were not available for many ofthe mouse
strains and stocks. Despite these limitations, how-
ever, the differences between mice at the extremes
of the ranking are significant.
SENCAR mice are between 10 and 20 times
more sensitive than CD-1 mice to DMBA tumor
initiation (10). However, SENCAR mice are only
between 3 and 5 times as sensitive as CD-1 mice to
B(a)P tumor initiation (10). SENCAR mice are 2 to
3 times as sensitive as CD-1 mice to TPA promotion
(9).
Between SENCAR and C57BL/6 micethere is an
even greater difference in sensitivity to two-stage
skin carcinogenesis. C57BL/6 mice are very refrac-
tory to two-stage skin carcinogenesis by B(a)P-
TPA. Even high initiating doses of B(a)P (1600
nmoles) and high promoting doses of TPA (10 ,ug)
are very ineffective in causing skin tumors (Slaga
andNesnow, unpublisheddata). However, C57BL/6
micedorespondtocompletecarcinogenesisbyB(a)P
(9). Such unequal susceptibility to complete and
two-stage carcinogenesis within a stock or strain of
mice strongly suggests that the promotional phases
of complete and two-stage carcinogenesis are dis-
similar. In addition, differences in sensitivity to
initiation and promotion between mice may be due
to alterations in the promotional phase oftwo-stage
carcinogenesis. In this regard, we recently found
that benzoyl peroxide is an effective promoter in
C57BL/6 and SENCAR mice (Slaga et al., unpub-
lished data). For some reason, TPA is not an effec-
tive promoter in C57BL/6 mice.
Tumor Promotion
An agentthatinducestumors whengivenrepeat-
edly after a subthreshold dose of a carcinogen is
referred to as a tumor promoter. Although the
phorbol esters are the most potent mouse skin
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Table 3. Dose-response studies on the ability of DMBA and B(a)P to initiate skin tumors in SENCAR mice.ab
Mean papillomas per Mice with papillomas Mice with carcinomas
Initiator Dose, nmole mouse at 15 weeks at 15 weeks, % at 50 weeks, %
DMBA 100 22 100 100
DMBA 10 6.8 100 40
DMBA 1 3.2 93 22
DMBA 0.1 0.5 20 5
B(a)P 200 7.5 100 55
B(a)P 100 3.2 78 30
B(a)P 50 1.4 60 18
aData of Slaga et al. (7).
bExperimental protocol: beginning 1 week after initiation, mice were treated twice weekly with 5 p.g TPA.
tumorpromoters, awidevarietyofothercompounds
are known to have skin tumor-promoting activity
(Table 4). After the phorbol esters and dihydro-
teleociden 'B, anthralin is the most potent tumor
promoter of those listed in Table 4. Van Duuren
and Goldschmidt (11) reported a fairly extensive
structure-activity study with anthralin and deriva-
tives. Likewise, Boutwell and Bosch (12) reported a
structure-activity study of a number of phenolic
compounds that are weak promoters in comparison
to the phorbol esters and anthralin. Although sev-
eral ofthe other compounds shown in Table 4 have
moderate to weak activity as tumor promoters, no
extensive structure-activity studies havebeenreport-
ed. We have recently found that benzo(e)pyrene
and benzoyl peroxide as well as other free radical-
generatingcompoundssuchaschloroperbenzoicacid
and lauroyl peroxide are relatively good tumor
promoters (13,14).
Table 4. Skin tumor promoters.a
Compound Potency
Croton oil Strong
Certain phorbol esters found in croton oil Strong
Some synthetic phorbol esters Strong
Certain euphorbia latices Strong
Anthralin Moderate
Certain fatty acids and fatty acid methyl esters Weak
Certain long chain alkanes Weak
Phenolic compounds Weak
Surface active agents (sodium lauryl sulfate, Weak
Tween 60)
Citrus oils Weak
Extracts ofunburned tobacco Moderate
Tobacco smoke condensate Moderate
losoacetic acid Weak
1-Fluoro-2,4-dinitrobenzene Moderate
Benzo(e)pyrene Moderate
Benzoyl peroxide Moderate
Dihydroteleocidin Strongb
aSee Slaga and Fischer (3) for individual citations.
bDihydroteleocidin 13 has a promoting potency similar to that
ofTPA (Slaga and Sugimura, unpublished results).
The ability of TPA to promote tumor yield with
respect to dose after DMBA initiation is shown in
Table 5. For tumor promotion (as for tumor initia-
tion, Table 3) a very good dose-response relation-
ship is seen when either the number of papillomas
per mouse at 15 weeks or the percentage of mice
with squamous cell carcinomas at 50 weeks is con-
sidered. Similar results have been reported from
studies using Charles River CD-1 mice (15) and
ICR/Ha Swiss mice (16).
Unlike the initiation phase, the promotion stage
requires acertain frequency ofapplication to induce
tumors and is reversible (8). In general, as the
frequency of TPA application decreases the pro-
moting activity also decreases (8). Even high doses
of TPA once every 2 or 3 weeks are ineffective in
tumor promotion (8).
Complete Carcinogenesis
Complete carcinogenesis in mouse skin refers to
the production oftumors (mainly carcinomas) after
repeated application ofa carcinogen for terms ofup
to 1 yr. Compounds possessing both tumor initiat-
ing activity and tumor promoting activity will pro-
duce tumors in this regimen. An examination ofsix
mouse stocks and strains usingB(a)P and DMBA as
the carcinogens (9) suggests the following ranking
forsensitivitytocompletecarcinogenesis: SENCAR
>CD-1 > C57BL/6
- BALB/c
- ICR/Ha Swiss >
C3H.
Complete carcinogenesis in mouse skin was used
in the early 1900's to identify carcinogens in organic
extracts oforganicparticulate samples and totry to
link these materials to the etiology of human can-
cer. Passey (17) found that ether extracts of coal
chimney soot produced both "warts" (papillomas)
and"cancers"(carcinomas)whenappliedrepetitively
to the depilitated backs of mice. Campbell (18)
confirmed these results with coal soot and also
reported the carcinogenic activity on mouse skin of
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Table 5. Dose-response studies on the ability of TPA to promote tumors after DMBA initiation in SENCAR mice.a'b
TPA dose, Time to first Mean papillomas per Mice with papillomas Mice with carcinomas
,ug papilloma, weeks mouse at 15 weeks at 15 weeks, % at 50 weeks, %
10 8 3.0 100 32
5 6 7.2 100 46
2 7 6.5 100 45
1 8 3.6 80 25
0.1 11 0.4 5 8
aData of Slaga et al. (7).
bExpermental protocol: At 1 week after initiation with 10 nmoles DMBA, mice were promoted with various doses of TPA.
road dust extracts. Remarkably, Campbell also
observed both dermal and lung tumors in mice
exposed only to road dust particulates (19).
Kotin and co-workers examined the carcinogenic
effects oforganic extracts ofairparticulate samples
from the Los Angeles area. These extracts pro-
duced both malignant and benign tumors when
applied repeatedly to the backs of C57BL/6 mice
(20). Wynder and Hoffmann expanded these stud-
ies by administering air particulate extracts from
the Detroit area to Swiss ICR mice (21). Both
groups concludedthatB(a)Palone couldnotaccount
forallthe carcinogenic activityobserved. Kotin and
his group (22) and Wynder and Hoffmann (23-25)
also studied the carcinogenic effects of organic
extracts of particulate emissions from gasoline
engines; both concluded that these extracts pro-
duce tumors on mice. Kotin et al. studied extracts
from particulates isolated from a diesel engine. In
contrast to the positive results reported for air
particulate and gasoline engine emissions, these
investigators found C57BL/6 mice to be refractory
to the diesel extracts (26). However, tumors were
produced in strain A mice treated repetitively with
the diesel mixtures (26). Von Haam and Mallette
(27) and V6samae (28) were able to induce tumors
in mice by applying extracts of industrial carbon
black and oil shale soot, respectively.
Most ofthe studies described above used limited
numbers ofmice ofvarious strains, did not explore
potential sex differences, and used limited numbers
of doses. These studies were not designed to pro-
duce comparative dose-response data.
We report here results from a study designed to
produce extensivedose-responseinformation, using
the same mouse strain (SENCAR), on the tumori-
genic and carcinogenic activities oforganic extracts
from a variety ofparticulate emission sources: die-
sel and gasoline vehicles, coke oven, and roofing
tar. Earlierpublications ofresultsfromtheseexper-
iments reported papilloma formation after 6 mo in
a tumor initiation protocol (6,29-32). This paper
reports the production of carcinomas after 1 yr in
both tumor initiation and complete carcinogenesis
protocols.
Materials and Methods
Sample Generation and Isolation
The details of sample generation and isolation
were reported previously (33). Vehicle emission
samples were obtained from a 1973 preproduction
Nissan-Datsun 220C (Nissan), a 1976 prototype
Volkswagen TurboRabbit (VW Rabbit), and a 1977
Ford Mustang II-302 V-8 with catalyst and EGR
(Mustang). Each vehicle was mounted on a chassis
dynamometer and driven in a repeated highway
fuel economy test (HWFET) cycle of 10.24 mi, an
average speed of 48 mph, and a running time of
12.75 min. The Nissan and VW Rabbit were fueled
with the same batch of No. 2 diesel fuel. The
Mustang was fueled with unleaded gasoline. Par-
ticulate samples were collected with a dilution tun-
nel in which the hot exhaust was diluted, cooled,
and filtered through Pallflex Teflon-coated fiber
glass filters.
Topside coke oven samples were collected from
the top of a coke oven battery at Republic Steel,
Gadsden, AL, by use of a massive air volume
sampler. Because of the topside ambient location
and local wind conditions, an unknown portion of
this emission sample contains particles from the
local urban environment. The coke oven main sam-
ple was collected from a separator located between
the gas collector and the primary coolers within the
coke oven battery.
The roofing tar emission sample was collected
from a conventional tar pot with external pro-
pane burner. Pitch-based tar was heated to 182-
193°C and emissions were collected with a 1.8-m
stack extension and Teflon socks in a baghouse.
Only one vehicle or source was used for each
sample; therefore, each sample may not be repre-
sentative of the particular technology. All samples
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were extracted by a Soxhlet apparatus with dichlo-
romethane, which was then removed by evapora-
tion under dry nitrogen gas.
Tumor Experiments
Seven- to nine-week-old SENCAR mice (8) bred
at Oak Ridge National Laboratory were used.
There were 80 animals (40 of each sex) per treat-
ment group. Animals were housed in plastic cages
(10 per cage) underyellow light with hardwood chip
bedding, fed Purina chow and water ad libitum, and
maintained at 22-230C with 10 changes of air per
hour. All mice were shaved with surgical clippers 2
days before the initial treatment, and only those
mice in the resting phase of the hair cycle were
used.
Under the tumor initiation protocol, all samples
at all doses were applied as a single topical treat-
ment in 0.2 mL spectral quality acetone, except for
the 10-mg dose, which was administered in doses of
2 mg for 5 days. Beginning 1 week after treatment,
2.0 ,ug TPA in 0.2 mL acetone was administered
topically twice weekly. Under the complete carci-
nogenesis protocol, samples were administered in
0.2 mL acetone weekly (or twice weekly for the
highest dose level) for 50 to 52 weeks. Under the
tumor promotion protocol, mice were first initiated
with 50.5 jig B(a)P in 0.2 mL acetone and then
treated weekly (or twice weekly for the highest
dose level) for 34 weeks with the sample.
Skin tumor formation was recorded weekly, and
papillomas >2 mmindiameter and carcinomas were
included in the cumulative totaliftheypersisted for
1 week or longer. The number ofmice with tumors,
the number ofmice surviving, and the total number
of tumors were determined and recorded weekly.
At 6 months, the number ofpapillomas per surviv-
ing animal was recorded for statistical purposes.
The tumors were histologically verified; also, non-
dermal tumors were histopathologically identified.
Statistical Analysis
Tumorincidence analyses were carried out onthe
papilloma data obtained at 6 mo and on the cumula-
tive numberofanimals with carcinomas at 1 yr. The
data were fitted to a probit model, taking into
account the numbers of spontaneous tumors occur-
ring in the control groups. The probit formula used
is
P = 130 + (1-130)4. (01 + 021nx)-
where P is the probit proportion, x is the dose
applied, and is the standard normal cumulative
distribution function (34). The model parameters
'P0o I1, and' 2, were estimated from the raw data
by maximum likelihood methods (35). The dose that
would produce a 50% tumor incidence in excess of
the control rate was then estimated as a function of
the model parameters. The 95% confidence limits
were estimated using the asymptotic variance-
covariance matrix estimated during the model-fit-
ting process. Chi-square goodness-of-fit and likeli-
hood ratio tests were also computed to examine the
appropriateness of the model and the strength of
the dose effect.
The papilloma scores at 6 months were also sub-
jected to tumor multiplicity analysis by a nonlinear
Poisson model (36):
i = Po + eP' + 2In (xi)
where'Xi is the number of papillomas per mouse,
xi is the dose, and"1o,'1l, and' 12 are the model
parameters. Using maximum likelihood methods,
the model parameters were estimated from the raw
data and used to calculate the number ofpapillomas
per mouse for a dose of 1 mg. Asymptotic 95%
confidenceintervalsfortheseactivitieswereobtained.
Tests for the Poisson assumption, adequacy of the
model, and strength ofthe dose response were also
calculated (36).
Results
Tumor Initiation
The tumor initiation experiments were designed
to compare the relativetumorigenic activities ofthe
diverse complex mixtures (Nissan, VW Rabbit,
Mustang, topside coke oven, coke oven main, and
roofingtarextracts) andB(a)P. Animalswerescored
at 6 months for papillomas and at 1 yr for carcino-
mas. The carcinoma data represent the cumulative
number of animals with carcinomas at 1 yr in each
treatment group regardless of survival.
The B(a)P, topside coke oven, coke oven main,
Nissan, androofingtarsamplesproduced an 89% or
greater tumor incidence at the highest dose level
applied (Tables 6, 7). Tumor multiplicity ranged
from five to six papillomas per mouse in the roofing
tar and Nissan groups to greater than seven in the
B(a)P, topsidecoke ovenandcoke ovenmaingroups.
These groups also produced significant numbers of
squamous cell carcinomas: 13 to 65% ofthe mice in
each group bore carcinomas at the highest dose
evaluated. In general, samples which produced a
papilloma response of greater than five papillomas
permouse at6monthsproduced acarcinomaresponse
of 0.15 to 0.65 carcinomas per mouse, with 13 to
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Table 6. Tumors observed following administration ofB(a)P, topside coke oven extract, and coke oven main extract toSENCAR
mice in the tumor initiation protocol.
Mice with Mean Mice with Mean
Dose, Mice papillomas, papillomas carcinomas, carcinomas per
Sample Fg/mouse Sex surviving %a per mousea %b mouseb
B(a)P 0 M 37 8 0.08 5 0.05
0 F 39 5 0.05 0 0
2.52 M 40 45 0.50 5 0.07
2.52 F 39 1 0.44 5 0.05
12.6 M 40 73 1.8 20 0.20
12.6 F 37 57 1.1 23 0.23
50.5 M 39 100 5.8 25 0.25
50.5 F 40 75 2.8 20 0.20
101 M 38 95 10.2 30 0.33
101 F 38 97 7.9 25 0.25
Topside coke oven 100 M 40 13 0.13 0 0
100 F 40 10 0.20 8 0.08
500 M 40 73 1.6 5 0.05
500 F 40 70 1.8 15 0.15
1000 M 37 95 2.6 15 0.15
1000 F 39 72 2.0 3 0.03
2000 M 39 95 4.0 13 0.13
2000 F 38 90 3.5 10 0.10
10000 M 39 100 7.1 13 0.15
10000 F 40 100 7.7 20 0.23
Coke oven main 100 M 38 50 0.63 10 0.10
100 F 39 31 0.38 25 0.25
500 M 39 90 3.7 54 0.59
500 F 39 92 2.2 54 0.54
1000 M 39 87 3.3 53 0.53
1000 F 39 90 3.1 48 0.48
2000 M 40 78 3.1 48 0.48
2000 F 40 100 5.3 45 0.45
10000 M 38 100 8.9 55 0.55
10000 F 37 100 8.1 65 0.65
aScored 6 mo after initiation.
bCumulative score 1 yr after initiation.
65% of the animals bearing at least one tumor at 1
yr.
The VW Rabbit sample (Table 7) produced dose-
related increases in papillomas in both male and
female mice, with the maximum activity for each
sex at 10 mg. At this dose there were 0.34 to 0.47
papillomas per mouse, with 24 to 42% ofthe animals
bearing tumors. Few carcinomas were scored at 1
yr.
The Mustang sample (Table 8) was tested at
doses of from 0.1 to 3 mg/mouse due to sample
limitations. Theresponsewasmaximalinthe females
at 3 mg/mouse and activity reached aplateau at 2 to
3 mg/mouse in the males. Of the female mice, 20%
developed carcinomas at the highest dose tested.
Theresponses atthehigherdoses weresignificantly
greater than those of the TPA controls (Table 6).
The lack ofa monotonic dose response across the
complete dose range tested of the VW Rabbit and
Mustang samples may indicate a toxic response to
these samples. Damage to the skin epidermal cells
with result in a lower tumorigenic response for
these complex mixtures. This is particularly clear
with the Mustang sample, where a 3-fold increase
in dose (from 1 to 3 mg/mouse) resulted in no
increase in tumor response.
Complete Carcinogenesis
Four agents were examined for their ability to
act as complete carcinogens in the SENCAR mouse
skin system: B(a)P, coke oven main extract, roofing
tar extract, and Nissan extract. Weekly applica-
tions of 50.5 ,ug B(a)P produced a carcinoma inci-
dence of greater than 93%, with almost one carci-
noma per mouse (Table 9). Higher doses did not
increasethe tumormultiplicity. Nocarcinomas were
observed in the control animals (Table 9).
The coke oven mainsample alsoproduced astrong
complete carcinogen response in both male and
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Table 7. Tumors observed following administration ofroofing tar extract, Nissan extract, and
mice in the tumor initiation protocol.
VW Rabbit extract to SENCAR
Mice with Mean Mice with Mean
Dose, Mice papillomas, papillomas carcinomas, carcinomas per
Sample pLg/mouse Sex surviving % per mousea %b mouseb
Roofing tar 100 M 40 10 0.13 5 0.05
100 F 39 15 0.21 10 0.10
500 M 40 28 0.35 10 0.10
500 F 39 13 0.15 18 0.18
1000 M 39 38 0.41 5 0.05
1000 F 40 45 0.80 15 0.15
2000 M 39 36 0.62 13 0.13
2000 F 38 37 0.45 15 0.15
10000 M 39 100 6.4 23 0.25
10000 F 40 95 5.7 48 0.48
Nissan 100 M 37 0 0 0 0
100 F 39 3 0.03 5 0.05
500 M 38 26 0.34 13 0.13
500 F 39 23 0.39 10 0.10
1000 M 40 33 0.38 20 0.20
1000 F 38 39 0.53 13 0.13
2000 M 35 66 1.1 13 0.13
2000 F 40 58 1.6 15 0.15
10000 M 38 89 5.5 36 0.36
10000 F 38 97 5.7 31 0.31
VW Rabbit 100 M 40 18 0.18 0 0
100 F 37 14 0.14 0 0
500 M 37 14 0.14 0 0
500 F 40 5 0.05 0 0
1000 M 38 21 0.21 3 0.03
1000 F 39 18 0.26 3 0.03
2000 M 38 21 0.24 5 0.05
2000 F 35 14 0.17 6 0.06
10000 M 38 24 0.34 5 0.05
10000 F 38 42 0.47 10 0.10
aScored 6 mo after initiation.
bCumulative score 1 yr after initiation.
Table 8. Tumors observed following administration of Mustang extract to SENCAR mice in the tumor initiation protocol.
Mice with Mean Mice with Mean
Dose, Mice papillomas, papillomas carcinomas, carcinomas per
gg/mouse Sex surviving %a per mousea %b mouseb
100 M 39 5 0.05 5 0.05
100 F 39 13 0.23 13 0.13
500 M 39 13 0.15 0 0
500 F 38 18 0.24 10 0.10
1000 M 40 18 0.18 5 0.05
1000 F 40 10 0.13 10 0.10
2000 M 37 22 0.24 15 0.15
2000 F 39 21 0.23 13 0.13
3000 M 34 18 0.24 5 0.05
3000 F 40 23 0.28 20 0.20
aScored 6 mo after initiation.
bCumulative score 1 yr after initiation.
female mice (Table 10). Male mice seemed to be
more sensitive: 98% of the males bore approxi-
matelyonecarcinoma, whileonly75%ofthefemales
responded. The roofing tar sample produced a
significant response only atthehighestdoseapplied
(4 mg/mouse/week), with 25 to 28% of the mice
bearing tumors.
The Nissan sample was essentially inactive as a
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Table 9. Tumors observed following administration ofB(a)P
to SENCAR mice in the complete carcinogenesis protocol.
Mice with Mean
Dose, ,ug/ carcinomas, carcinomas
mouse/week Sex %a per mousea
0 M 0 0
0 F 0 0
12.6 M 10 0.10
12.6 F 8 0.08
25.2 M 63 0.63
25.2 F 43 0.43
50.5 M 93 0.93
50.5 F 98 0.98
101 M 80 0.83
101 F 90 0.98
202 M 80 0.80
202 F 93 0.98
aCumulative score after 1 yr.
complete carcinogen at the doses applied (Table
10).
Tumor Promotion
The coke oven main and roofing tar samples were
applied weekly to mice previously initiated with a
single dose of 50.5 jig B(a)P. The coke oven main
sample was 1/1000 as active as TPA (Table 11). The
roofing tar was also active as a tumor promoter and
produced a dose-related effect up to the highest
dose applied. Mice treated with only asingle dose of
B(a)P produced no tumors.
Quantitative Analysis
The data were subjected to computer modeling
and statistical procedures specifically designed for
Table 10. Tumors observed following administration of coke oven main extract, roofing tar extract, and Nissan extract to
SENCAR mice in the complete carcinogenesis protocol.
Mice with carcinomas, %V Mean carcinomas per mousea
Dose, ,g/ Coke oven Roofing Coke oven Roofing
mouse/week Sex main tar Nissan main tar Nissan
100 M 5 0 0 0.05 0 0
100 F 5 0 0 0.05 0 0
500 M 36 0 0 0.36 0 0
500 F 30 0 0 0.30 0 0
1000 M 48 3 0 0.55 0.03 0
1000 F 60 0 0 0.60 0 0
2000 M 82 3 0 1.00 0.03 0
2000 F 78 8 0 0.78 0.08 0
4000 M 98 25 3 0.98 0.28 0.03
4000 F 75 28 5 0.85 0.28 0.05
aCumulative score after 1 yr.
Table 11. Tumors observed following administration ofcoke oven main extract and roofing tar extract to SENCAR mice in the
tumor promotion protocol.
Mice with papillomas, %a Mean papillomas per mouse'
Dose,
,ug/mouse/week Sex Coke oven main Roofing tar Coke oven main Roofing tar
ob M 0 0 0 0
ob F 0 0 0 0
100C M 3 0 0.02 0
10oC F 10 0 0.10 0
500 M 26 5 0.44 0.05
500 F 38 0 0.83 0
1000 M 53 20 1.2 0.27
1000 F 68 16 1.2 0.36
2000 M 84 23 2.5 0.32
2000 F 85 13 3.1 0.15
4000d M 100 55 8.2 1.2
4000d F 100 30 8.8 0.6
TPA, 4 ,uge M 86 100 3.1 5.2
TPA, 4 ,uge F 97 100 5.9 7.2
aScored at 34 weeks.
bMice initiated with 50.5 ,ug B(a)P and subsequently treated weekly with acetone.
cMice initiated with 50.5 ,ug B(a)P and subsequently treated weekly with coke oven main or roofing tar extract.
dMice initiated with 50.5 ,g B(a)P and subsequently treated twice weekly with 2 mg coke oven main or roofing tar extract.
eMice initiated with 50.5 ,ug B(a)P and subsequently treated twice weekly with 2 ,ug TPA.
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the analysis of tumor multiplicity and incidence
data using an interactive computer terminal graph-
ics system. Tumor incidence data were applied to a
probit modelwith background correction. Fromthe
model, the dose that would elicit tumors in 50% of
the surviving animals in excess of the control rate
(TD50) was estimated. An example of this probit
analysis (papilloma data, Nissan sample) is shown
in Figure 1. The value of TD50 and the associated
95% confidence intervals calculated from the fitted
parameters are shown as well as the raw data. In
Table 12, such estimates are presented only if the
TEST AGENT CODE: 6651 PROTOCOL: TI STRAIN: S SEX: N MEEK: 26
TEST AGENT NME: NISSAN DCM 1979 START DATE: 072679
DOSE *NICE %PAPS MEAN S.D.
.666 37 6.166 .601 .277
100.666 37 .666 .660 .606
566.66 38 26.316 .342 .627
166". 46 32.566 .375 .586
2666.66 35 65.714 1.143 1.167
16666.666 39 69.474 5.474 3.269
PROBIT MOEL WITH BACKGROUND
ESTIMATES
BETA INITIAL FINAL ASYN VAR in_
---- --- ---- --- ----------- %
6 .6611 .6446 .666S5
1 -2.5263 -5.6797 .7466 N
2 .3671 .7671 .6133 I
T -
TEST CHI-So DF P H 55-
G-O-F 5.75 3 .1243 P -
DOSE 162.92 2 .6060 A -
ESTIMATE LONER 95% UPPER S
ED50 1522.95 11".93 216.75 6-
TD56 1642.16 1269.64 2229.17
OBS & EXP US DOSE
, . I I . . . .
5666
MICROGRAMS
16
FIGURE 1. Computer-generated Probit analysis of tumor inci-
dence. Computergraphic output ofsample identification; raw
data; initial and final parameter estimates; (---) TD50 esti-
mates with 95% confidence intervals; ( ) plot ofexpected
response (solid line) and (x) observed responses.
observed data adequately fit the calculated model.
The TD50 values ranged from 0.0036 to 2.1 mg;
B(a)P was the most active sample and roofing tar
extract was the least active sample. The VW Rab-
bit and Mustang experiments did not result in any
tumor incidences of 50% or more, and calculations
were not made for these samples. Within the 95%
confidence bands, there were no sex differences for
any sample.
Tumor multiplicity data were analyzed by a non-
linear Poisson model with a background correction
term. The data were fitted to the model and the
model parameters were estimated; from these val-
ues the number of papillomas per mouse at 1 mg
and the associated 95 % confidence intervals were
estimated. An example of the graphics display is
shown in Figure 2. The calculated tumor multiplic-
ity data ranged from 0.17 to 2.2 papillomas per
mouse, a 10-fold range (Table 12). Data from the
B(a)P experiments could not be used, since they
were not obtained in the 1-mg dose range, but
linear extrapolation from the 0.1-mg dose used
yields an estimate of 79 to 100 papillomas per
mouse. No sex differences were evident from anyof
these calculations.
The carcinoma incidence data (tumor initiation
andcompletecarcinogenesisprotocols) wereapplied
to the probit model. Estimates for B(a)P and the
coke oven main sample are compared in Table 13.
With the coke oven main sample, the estimated
values ofTD50 are similar for both the tumor initia-
tion (single application) and complete carcinogene-
sis (weekly application) protocols. However, B(a)P
as a tumor initiator was much less effective in
Table 12. Nonlinear Poisson and probit model estimates based on papilloma incidence at 6 mo in SENCAR mice in the tumor
initiation protocol.
Nonlinear Poisson Probit
Papillomas/mouse 95% confidence Dose for 50% papilloma 95% confidence
Sample Sex at 1 mg intervals incidence (TD50), mg intervals
B(a)P M NCa 0.0036 0.0021 - 0.0062
F NCa 0.0091 0.0057 - 0.015
Coke oven main M NDb 0.079 0.027 - 0.23
F NDb 0.19 0.14 - 0.28
Topside coke oven M 2.2c 2.00-2.40 0.30 0.22 - 0.40
F 2.0c 1.90-2.20 0.42 0.31 - 0.58
Nissan M 0.49c 0.38-0.63 1.60 1.2 - 2.2
F 0.68c 0.57-0.79 1.50 1.1 - 1.9
Roofing tar M 0.38c 0.30-0.49 1.8 1.2 - 2.7
F 0.44c 0.35-0.55 2.1 1.5 - 2.8
VW Rabbit M 0.21 0.14-0.30 NCd
F 0.17 0.11-0.25 NCd
Mustang M 0.17 0.12-0.24 NCd
aNot calculated since data were obtained at a lower dose range.
bNot determined.
'The distribution of tumors at some dose levels was not Poisson, as the variances exceeded the means.
dNot calculated since tumor incidence did not exceed 50%.
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TEST AGENT CODE: 6651 PROTOCOL: TI STRAIN: S SEX: WEEK: 26
TEST AGENT NANE: NISSAN DCM 1979 START DATE: 072879
DOSE #MICE %PAPS MEAN S.D.
.600 37 8.108 .081 .277
166.60 37 .000 .086 .066
586.6OO 38 26.316 .342 .627
1000.600 40 32.500 .375 .586
2000.86. 35 65.714 1.143 1.167
10060.000 38 89.474 5.474 3.269
NONLIN POISSON MODEL
WITH BACKGROUND
ESTIMATES
RETA INITIAL FINAL ASYM VAR
0 .0811 .6456 .0807
1 -1.7991 -8.3276 .4138
2 .3137 1.6888 .6051
TEST CHI-SQ DF P
POISS 222.34 219 .4244
ADOCY 9.86 3 .0198
DOSE 515.58 2 .6006
PAPS/' 1 MIG LOWER 95X UPPER
SPEC .492 .362 .634
EXCS .447 .329 .607
O8S L EXP VS DOSE
MICROGRAMS
FIGURE 2. Computer-generated nonlinear Poisson analysis of
tumor multiplicity data. Computer graphic output of sample
identification; raw data; initial and final parameter estimates;
estimated papillomas/mouse at 1 mg with 95% confidence
intervals; ( --) plot ofexpected response and (x) observed
responses.
producing carcinomas than was the B(a)P as a
complete carcinogen. When the comparison was
made on the total amount applied to the mice, the
tumor initiation protocol was more sensitive than
thecompletecarcinogenesisprotocolforbothagents.
Discussion
The SENCAR mouse, specifically bred for in-
creasedsensitivitytotwo-stage(initiation-promotion)
carcinogenesis, has demonstrated its responsivity
to carcinogens (10,38,39). Of mouse strains and
stocks examined, the SENCAR mouse was most
sensitive to the initiating and complete carcinogenic
effects of B(a)P and DMBA (9,10).
These studies ofthe effects of complex mixtures
and B(a)P on SENCAR mouse skin are the most
extensive to date, and the results confirm the appli-
cability of this mouse strain to the analysis of
complex mixtures.
The B(a)P, coke oven main, and roofing tar sam-
ples were positive in both sexes as tumor initiators,
producingbothpapillomas and carcinomas, and were
also positive as tumor promoters and complete car-
cinogens. In general, those agents which produced
a strong tumor-initiation papilloma response also
produced carcinomas in the same animals when
scored at 1 yr. The two diesel engine samples were
positive as tumor initiators, as was the unleaded
gasoline engine sample. Additional work with emis-
sion extracts from other diesel vehicles and engines
has demonstrated theiractivity as mouse skin tumor
initiators (6,31,32).
Of the strong tumor initiators (B(a)P, coke oven
main, roofing tar, Nissan), only Nissan was not also
a complete carcinogen at the doses tested. Kotin et
al. (26) did obtain tumors from diesel particulate
extract on strain A mice; this indicates that higher
doses mightinduce tumors in SENCAR mice. How-
ever, on a weight basis, coke oven main and roofing
tar are much more active than Nissan as complete
carcinogens.
Of the strong tumor initiators (B(a)P, coke oven
main, roofing tar, Nissan), only Nissan seemed not
to possess tumor-promotingactivity. The presumed
lack oftumor-promoting activity in the Nissan sam-
ple is probably as function ofthe composition ofthe
Nissan mixture. The skin tumorigenesis results
results indicate that the coke oven main sample was
a stronger tumor promoter than the roofing tar
sample. Chemical fractionation and mutagenesis
studies of the diesel, roofing tar, and coke oven
main samples show that both the chemical composi-
tion of the fractions and their capacities to induce
genetic alteration are significantly different (J.
Lewtas, personal communication).
Chemicals which seem to only be tumor initiators
on mouse skin may also possess complete carcino-
genic activity when administered by other routes to
miceandrats. Urethane (40) andtriethylenemelamine
(41) are both probably pure mouse skin tumor initi-
ators: repeated applications ofthese agents on mouse
skindo notyieldtumors. However, urethane admin-
istered intraperitoneally, subcutaneously, or orally
Table 13. Comparison ofprobit model estimates based on cumulative carcinoma incidence at 1 yr in SENCAR mice in the tumor
initiation and complete carcinogenesis protocols.
Tumor inititationa Complete carcinogenesisb
Dose for 50% 95% confidence Dose for 50% 95% confidence
Sample Sex carcinoma (TD50), mg intervals carcinoma (TD50), mg intervals
B(a)P M > 0.10 - 0.025 0.017-0.037
F > 0.10 - 0.029 0.023-0.036
Coke oven main M 1.9 0.83-4.4 0.78 0.62 -0.99
F 1.5 0.57-3.7 0.93 0.69 -1.2
aEstimates based on single dose administration.
bEstimates based on weekly dose administration.
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to mice produces a variety of lesions, including
lung, liver, and lymphoid tumors. Urethane admin-
istered orally to rats also produces multiple tumors
(40). Triethylenemelamine produces lung tumors in
miceafterintraperitoneal injectionandmuscletumors
in rats after subcutaneous injection (41).
It is compelling to postulate that the B(a)P in
these complex mixtures accounts for their tumori-
genic activity, since mouse skin is exquisitely sensi-
tivetothis agent. Theresults presented herereveal
that a single application ofless than 5 pug B(a)P as a
tumor initiator yields a 50% tumor incidence. How-
ever, the relationship between the B(a)P content of
each mixture and the papilloma response for each
mixture is not linear (Fig. 3). Probably none ofthe
activity of the coke oven sample can be explained
by B(a)P content, as the B(a)P-induced tumor
response at the B(a)P level in the coke oven sample
is quite small. Even the B(a)P level in the Nissan
sample (11 ,ug/10 mg extract) can only account for
20 to 30% ofthe papilloma response elicited by the
Nissan sample. This conclusion has also been stated
by Kotin et al. (20) and Wynder and Hoffmann (21),
based on the analysis of other complex mixtures.
Other components of the mixtures may play an
important role in their tumorigenic activities. For
example, 'p-propiolactone, a mouse skin tumor
initiator, has been identified in diesel exhaust par-
ticulate extracts (42).
Quantitative methods for the analysis of tumor
data are many and employ tumor incidence, tumor
multiplicity, and tumor latency data. Statistical
methods have been employed using Poisson and
other distribution assumptions, as well as both
uni-and multivariate analytical approaches (43-46).
We chose to apply a nonlinear Poisson model to the
papilloma incidence data. This model assumes a
Poisson distribution of tumors, that tumor multi-
10.0
9.0
8.0 Coke Oven
! 7.0
6.0 _ Roof- 5- 0 Tar 5.0 N~~~~~~~~~~~issan
o 4.0
g-3.0-
9L 2.0 Benzo(o)pyrene
2.0
1.0 VW Rabbit
0.01 Olds 0.10 1.00 10.00 100.00
Cot Benzo(a)pyrene, j g
FIGURE 3. Skin tumor initiating activities ofpure B(a)P and of
six complex mixtures. The tumor and B(a)P concentration
data are from the results obtained at the 10-mg dose of
complex mixture. CAT is a diesel sample not described in
this paper.
plicity is related to dose, that the response may be
nonlinear, and that there is abackground response.
Results from the nonlinear Poisson model suggest
the following ranking: topside coke oven > Nis-
san
- roofing tar
- VW Rabbit = Mustang. The
values calculated are only estimates and in some
cases the Poisson assumption made to derive the es-
timates is only partially fulfilled.
A probit model was chosen to evaluate the tumor
incidence data. The probit model examines animals
with tumors (regardless ofmultiplicity) and animals
without tumors. Results from the probit analysis
suggest the following ranking: B(a)P > coke oven
main3 topside coke oven > Nissan = roofing tar.
These are not the only models that can be applied to
these data, and although they appear effective in
this case, more effort is being placed in improving
statistical and modeling techniques.
Inadditiontothetumorigenesis studiesdescribed
above, detailed gross and histopathological analy-
ses ofselected animalshavebeenundertaken. Results
from these detailed pathological studies on the for-
mation ofinternal tumors and on the appearance of
tumors with longer latency periods will be pre-
sented at a later date.
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